9 May 2020 - Companies could switch from primarily making generics to producing higher-margin licensed drugs.
Nothing in Yusuf Hamied’s 60 years at Cipla, an Indian drug maker where he is chairman, prepared him for COVID-19. Production at its 30 plants fell by 70% nearly overnight in March as India’s government ordered a lockdown that made it hard for its 23,000 employees to work.
Critical inputs, from packaging to active ingredients, became scarce. The price of some sourced from China shot up five-fold.